Stock FLGT FULGENT GENETICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Fulgent Genetics, Inc.

Equities

FLGT

US3596641098

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
21.39 USD +1.18% Intraday chart for Fulgent Genetics, Inc. -4.93% -26.01%
May. 03 Transcript : Fulgent Genetics, Inc., Q1 2024 Earnings Call, May 03, 2024
May. 03 Earnings Flash (FLGT) FULGENT GENETICS Posts Q1 Revenue $64.5M MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
BU
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
BU
Fulgent Reports First Quarter 2024 Financial Results
AQ
Fulgent Reports First Quarter 2024 Financial Results
BU
Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
BU
Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
BU
Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024
BU
Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic Testing
PR
Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference
BU
Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting
BU
Fulgent Reports Third Quarter 2023 Financial Results
BU
Fulgent Announces Two Poster Presentations at SITC 2023 Annual Meeting
BU
Fulgent Genetics to Announce Third Quarter 2023 Financial Results on Friday November 3, 2023
BU
Fulgent Reports Second Quarter 2023 Financial Results
AQ
Fulgent Reports Second Quarter 2023 Financial Results
BU
Fulgent Genetics to Announce Second Quarter 2023 Financial Results on Friday, August 4, 2023
BU
Fulgent Data at ASCO 2023 Highlights Progress for Its Lead Therapeutic Oncology Candidate, FID-007, in Various Cancers
BU
FULGENT GENETICS, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2023 Annual Meeting
BU
FULGENT GENETICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FLGT Stock
  4. News Fulgent Genetics, Inc.
  5. Press Releases